Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Inoviq Ltd ( (AU:IIQ) ) is now available.
INOVIQ Limited has announced the creation of a Medical and Scientific Advisory Board (MSAB) aimed at providing expert guidance on its diagnostic and therapeutic programs. This board includes internationally recognized clinical researchers and oncologists with expertise in exosome science, cancer diagnostics, clinical trials, and cancer treatment. The advisory board’s guidance will support INOVIQ’s development milestones and clinical trials, potentially strengthening its positioning within the cancer diagnostics and therapeutics industry. This strategic move is expected to enhance the company’s research capabilities and contribute to the advancement of cancer diagnostics and treatments, with implications for improved patient outcomes.
More about Inoviq Ltd
INOVIQ Ltd is a biotechnology company that focuses on pioneering next-generation diagnostics and therapeutics for cancer. The company has commercialized its EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and offers the hTERT test as an adjunct test for bladder cancer. INOVIQ is advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, as well as early-stage exosome therapeutics for solid tumors.
YTD Price Performance: -16.50%
Average Trading Volume: 126,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$47.96M
See more insights into IIQ stock on TipRanks’ Stock Analysis page.
